C86.6
Primary cutaneous CD30-positive T-cell proliferations
Clinical Classification Guidelines
Inclusion Terms
- Lymphomatoid papulosis
- Primary cutaneous anaplastic large cell lymphoma
- Primary cutaneous CD30-positive large T-cell lymphoma
Medical Intelligence & Overview
Primary cutaneous CD30-positive T-cell proliferations are a group of rare skin conditions characterized by the abnormal growth of T-lymphocytes that express the CD30 protein. These conditions include lymphomatoid papulosis, primary cutaneous anaplastic large cell lymphoma, and primary cutaneous CD30-positive large T-cell lymphoma. While they share common features, each has distinct clinical and pathological characteristics. Usually presenting as skin lesions, these conditions are part of the spectrum of cutaneous lymphomas, a subgroup of non-Hodgkin lymphomas confined to the skin.
Causes & Symptoms
Clinical Causes: Genetic predisposition leading to abnormal T-cell growth Potential triggers such as infections or immune responses Unknown exact cause in many cases
Key Symptoms: Gradually appearing skin lesions that may be papules, nodules, or plaques Lesions typically localized but can be widespread Lesions often itchy or sometimes painless Lesions may ulcerate or become necrotic in some cases Potential for spontaneous regression or persistence over time
Diagnostic & Treatment
Diagnosis Path: Diagnosis involves a combination of clinical examination and laboratory tests. A dermatologist may perform a biopsy of the skin lesions to examine tissue under a microscope, revealing characteristic cell types and growth patterns. Immunohistochemical staining detects CD30 expression on the abnormal T-cells, confirming the diagnosis. Additional tests, including imaging or blood tests, might be performed to rule out systemic involvement or other conditions.
Treatment Protocols: Treatment options vary depending on the specific diagnosis, extent, and progression. Common approaches include: -#### Monitoring: - Some cases, especially lymphomatoid papulosis, may resolve spontaneously without aggressive treatment. -#### Phototherapy: - Ultraviolet light therapy can be effective for skin lesions. -#### Topical treatments: - Steroid creams or other topical agents may reduce inflammation. -#### Systemic therapies: - In more persistent or widespread cases, options like chemotherapy, targeted therapy, or immunotherapy might be considered. -#### Surgical excision: - For isolated or accessible lesions, removal might be recommended. Given the varied nature of these conditions, management plans are tailored to individual patient circumstances with input from a specialist in dermatology or hematology-oncology.
Clinical Advice & FAQs
Billing Guidance
Is C86.6 a billable ICD-10 code?
Yes, C86.6 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C86.6?
Clinical documentation must specify the nature of Primary cutaneous CD30-positive T-cell proliferations and any associated comorbidities for accurate reporting.
Cite this Clinical Reference